Compare · AIMT vs REXN
AIMT vs REXN
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and Rexahn Pharmaceuticals, Inc. (REXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and REXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Aimmune Therapeutics, Inc.
- Rexahn Pharmaceuticals, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest REXN
- MaxCyte Appoints Douglas Swirsky As Chief Financial Officer
- MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
- Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
- Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
- SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, REXN, and WPX Shareholders About Its Ongoing Investigations